Markets:

Overview

News

Currencies

International

Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

15.29 +0.20 (+1.33%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >

83 Biggest Movers From Yesterday ↗

June 09, 2022

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 08, 2022

Via Benzinga

38 Stocks Moving In Friday's Mid-Day Session ↗

May 20, 2022

Gainers Leju Holdings Limited (NYSE: LEJU) surged 27.8% to $4.0413.

Via Benzinga

20 Stocks Moving in Friday's Pre-Market Session ↗

May 20, 2022

Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 28.1% to $0.1550 in pre-market trading. Exicure said in Form4 filing a director bought 1,472,126 shares at average price of $0.19 per share.

Via Benzinga

76 Biggest Movers From Yesterday ↗

May 19, 2022

Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to...

Via Benzinga

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas ↗

May 13, 2022

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The...

Via Benzinga

Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund ↗

May 07, 2022

One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in...

Via Talk Markets

66 Biggest Movers From Yesterday ↗

May 03, 2022

Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged...

Via Benzinga

HFCAA News: 128 Chinese Stocks the SEC Could Delist ↗

May 05, 2022

The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 02, 2022

Via Benzinga

31 Stocks Moving In Monday's Mid-Day Session ↗

May 02, 2022

Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48...

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower; US Factory Growth Slows In April ↗

May 02, 2022

U.S. stocks traded mostly lower this morning, with the Dow Jones tumbling around 100 points on Monday.

Via Benzinga

U.S. FDA Rejects HUTCHMED's New Drug Application For Surufatinib In Neuroendocrine Tumors ↗

May 02, 2022

HUTCHMED (China) Limited (Nasdaq: HCM) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Surufatinib for the treatment of...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 02, 2022

Via Benzinga

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗

April 24, 2022

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...

Via Benzinga

Week In Review: Wuhan Binhui Raises $47 Million For Oncolytic Virus Products ↗

April 23, 2022

Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing...

Via Talk Markets

The Gift Chinese Regulators Just Gave Tech Stocks Like Alibaba And BeiGene ↗

April 04, 2022

Auditing issues persist for some 270 companies trading in the U.S. But they could ease.

Via Investor's Business Daily

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework ↗

April 01, 2022

Via Benzinga

Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs ↗

March 28, 2022

As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China.

Via InvestorPlace

Which Chinese Stocks Could Get Delisted? 6 Companies to Watch. ↗

March 25, 2022

Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way.

Via InvestorPlace

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today? ↗

March 11, 2022

Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next.

Via InvestorPlace

What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today ↗

March 11, 2022

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM...

Via Benzinga

Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat ↗

March 11, 2022

Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO...

Via Benzinga

Chinese Stocks Are Falling: What's Going On? ↗

March 10, 2022

Shares of multiple Chinese companies are trading lower Thursday following reports the U.S. Securities and Exchange Commision has identified multiple US-listed ADRs as...

Via Benzinga

Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble ↗

March 10, 2022

The SEC is calling out a several stocks for non-compliance. Could they face delisting?

Via Investor's Business Daily

Hutchmed Clocks Over 50% Jump In FY21 Sales Boosted By Three Oncology Drugs, Announces CEO Transition ↗

March 03, 2022

Hutchmed (China) Limited (NASDAQ: HCM) reported FY21 sales of $356.1 million, up 56% Y/Y, driven by commercial progress on three in-house developed oncology drugs...

Via Benzinga

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

Week In Review: Biopharma Deals Slow During Chinese New Year Week ↗

February 05, 2022

Amid a slow week, Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio is an early R&D company that was incubated by Sunshine...

Via Talk Markets

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

Headline News about HUTCHMED (China) Limited - American Depositary Shares

Starting at $3.75/week.

Subscribe Today